We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia (EIGEAPFD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01226134
Recruitment Status : Unknown
Verified July 2010 by Aga Khan University.
Recruitment status was:  Recruiting
First Posted : October 22, 2010
Last Update Posted : October 22, 2010
Sponsor:
Information provided by:
Aga Khan University

Brief Summary:

Pathogenesis of functional dyspepsia is poorly understood. Gastrointestinal motor abnormalities, Helicobacter pylori infection, impaired gastric accommodation to a meal, hypersensitivity of the afferent nerves of the gut, psychological disturbances and central nervous system dysfunction have been proposed.

Pharmacological treatments for patients with functional dyspepsia remain unsatisfactory. Only small benefits relative to placebo have been found with histamine H2 receptor antagonists, proton pump inhibitor and Helicobacter pylori eradication.

Itopride is a dopamine antagonist with acetylcholinesterase inhibitory actions. This agent is currently indicated for patients with various upper GI symptoms.

This study is aimed to evaluate the effect of Itopride on gastric emptying(by 13-C Octanoic acid breath Test), accommodation (by Gastric Scintigraphy SPECT and slow nutrient drinking test)and symptoms in FD patients


Condition or disease Intervention/treatment
Functional Dyspepsia Gastric Emptying Gastric Accommodation Drug: Itopride, Drug: Placebo

Detailed Description:
phase3 clinical trial

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia
Study Start Date : February 2009
Estimated Primary Completion Date : March 2011
Estimated Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Indigestion
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1.Itopride Group
The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
Drug: Itopride,
Itopride,50 mg capsules,thrice a day,for Four weeks
Other Name: Gananton
Placebo Comparator: 2.Control placebo group
The control group will receive placebo tablets for four weeks
Drug: Placebo
placebo capsules,thrice a day for four weeks



Primary Outcome Measures :
  1. To assess the effect of Itopride on Gastric Emptying,accommodation and capacity of tolerating a nutrient drink in patients with Functional Dyspepsia [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. To assess the effect of Itopride on symptom improvement in patient with Functional Dyspepsia [ Time Frame: 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All adult male or non-pregnant female patients who are diagnosed as functional dyspepsia and fulfilling Rome III criteria (1) will be considered
  2. Patients should be negative for H. pylori on gastric biopsy and Urea Breath Test.
  3. duodenal biopsy in these patients should be negative for giardiasis or celiac disease or any other established organic pathology
  4. A normal upper abdominal ultrasound
  5. Willing to participate and give consent for participation in the study.

Exclusion Criteria:

  1. Age <18 years
  2. Helicobacter Pylori positive on gastric biopsy and / or UBT.
  3. Taking other medications that alter gastric motility like macrolide

    • anti-emetics and antibiotics .
  4. Pregnant or breast-feeding females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01226134


Contacts
Contact: Shahab Abid, MD +92 21 4864656 ext 4656 shahab.abid@aku.edu
Contact: Wasim Jafri, MD +92 21 4864659 ext 4659 wasim.jafri@aku.edu

Locations
Pakistan
Aga Khan University Recruiting
Karachi, Sindh, Pakistan, 74800
Principal Investigator: Shahab Abid, MD         
Sub-Investigator: Wasim Jafri, MD         
Sub-Investigator: Maseeh Uzzaman, MD         
Sub-Investigator: Rakhshanda Bilal         
Sub-Investigator: Soobia Siddiqui, MD         
Sub-Investigator: Greger Lindberg, MD,PhD         
Sponsors and Collaborators
Aga Khan University
Investigators
Principal Investigator: Shahab Abid, MD Aga Khan University

Responsible Party: Dr. Shahab Abid, Aga Khan University,Karachi, Pakistan
ClinicalTrials.gov Identifier: NCT01226134     History of Changes
Other Study ID Numbers: 965-Med/ERC-08
First Posted: October 22, 2010    Key Record Dates
Last Update Posted: October 22, 2010
Last Verified: July 2010

Keywords provided by Aga Khan University:
Functional Dyspepsia
Itopride
Gastric Emptying
Gastric Accommodation
Dyspeptic Symptoms

Additional relevant MeSH terms:
Dyspepsia
Gastritis
Signs and Symptoms, Digestive
Signs and Symptoms
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases